A Phase 2 interventional study of ALN-PCSSC and Normal Saline in Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia and Diabetes, sponsored by The Medicines Company. Completed at 54 sites in 5 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-05-17.
Sponsored by The Medicines Company (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing inclisiran in Atherosclerosis — 3 open to participants now, 7 under way, 4 of them phase 3. inclisiran · Atherosclerosis.
Among the 16 studies testing inclisiran in Atherosclerosis, this one is the 6th largest by enrollment, is the only one that started in 2016, is one of 2 in phase 2, and was the 1st registered.
1,519 studies on the registry are indexed under Atherosclerosis; 225 are open to participants now.
Browse Atherosclerosis studies →3 of the 16 studies testing inclisiran in Atherosclerosis are open now, in 4 countries. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
Novartis Pharmaceuticals · Sites in Argentina, Brazil
Ages 18–100
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 30–50
By country, each count listing its studies:
inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 161 Atherosclerosis studies recruiting now, 84 (52%) set no upper age limit and 33 (20%) stop at 75 or younger; 16 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 501 is above the median of 100 across 880 interventional studies indexed under Atherosclerosis.
Median enrollment 401 across the 16 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 16 have an industry lead sponsor. The 8 most frequent:
This study is registered under The Medicines Company, one of the names counted as Novartis. Under that name alone:
The Medicines Company is the lead sponsor of 50 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
27 studies in Atherosclerosis by Novartis: 4 open now, 10 under way, 3 of them phase 3. Of 16 finished, 10 (63%) have results posted.
Among the 27 studies in Atherosclerosis by Novartis, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2016, is one of 4 in phase 2, and was the 6th registered.
Novartis’s Atherosclerosis studies by the year they started, since 2006.
4 of the studies testing inclisiran in Atherosclerosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06501443Novartis PharmaceuticalsLATAM LOWERS LDL-C | 2026-11-27 |
| NCT06249165Duke UniversityVictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease | 2026-12-31 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies testing inclisiran in Atherosclerosis, from their registry updates:
Among Novartis’s 27 in Atherosclerosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a Phase II, placebo-controlled, double-blind, randomized trial in 480 participants with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents (for example, diabetes and familial hypercholesterolemia) and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy, safety, and tolerability of ALN-PCSSC injection(s).
Participants will be screened and 480 eligible participants will be randomized: 60 participants per each of six ALN-PCSSC dose groups plus 120 participants total across the placebo groups (20 participants each to match each of the six drug dose groups). Treatment allocation will be stratified by country and by current use of statins or other lipid-modifying therapies. Each participant will receive either one or two injections on Day 1 or a single injection on Day 1 and on Day 90 of blinded ALN-PCSSC or placebo.
Formation of anti-drug antibodies (ADA) will be assessed on Day 1 (prior to and 4 hours after the injection) and on Days 30, 60, 90, 120, 150, 180 (Days 150 and 180 only in participants who receive a second dose of study drug), and 210 or until any ADA response becomes negative within the study duration.
The independent Data Monitoring Committee (DMC) will review safety data beginning after the first 40 participants receive the first injection of ALN-PCSSC or placebo and complete the Day 14 follow-up visit. Thereafter, the DMC will review safety data every 2 months until the end of the trial. A recommendation may be taken to stop or amend the study at any of these reviews.
On Day 1, all eligible participants will be randomized and receive the first subcutaneous (SC) administration of ALN-PCSSC or placebo. After the first study drug administration, the participant will be observed in the clinic for at least 4 hours post injection before being discharged. Participants will return at Day 14 and then at monthly intervals for 6 months. Participants randomized to receive a second dose of study drug will receive the second injection of ALN-PCSSC or placebo at the Day 90 visit.
Efficacy assessments will include the measurement of the effects of ALN-PCSSC on levels of LDL-C lipids and lipoproteins including total cholesterol (TC), triglycerides, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, very low-density lipoprotein (VLDL), apolipoprotein A1 (Apo-AI), apolipoprotein B (Apo-B), lipoprotein (a) [Lp(a)], C-reactive protein (CRP), and proprotein convertase subtilisin/kexin type 9 (PCSK9).
End of study (EOS) evaluations will be conducted at the EOS visit (Day 210). The expected duration of the participants' involvement in the study will be approximately 374 days, which includes screening, study drug administration, the course of single or multiple injections, and the follow-up period to Day 360.
Participants completing the study to Day 210 will be given the opportunity to enroll in a separate long-term extension study. Any participants in whom LDL-C levels have not returned to >80% of baseline values will continue to be followed as part of this study until either this level has been reached or until a maximum of Day 360, at which point they will be given the opportunity to enroll in the long-term extension study. At each visit, LDL-C levels, adverse events, serious adverse events, concomitant medications, and safety laboratory assessments will be collected.
Objectives:
Primary:
To evaluate the effect of ALN-PCSSC treatment on LDL-C levels at Day 180.
Secondary:
To evaluate the effect of ALN-PCSSC on the following:
Exploratory:
To collect/evaluate the effect of ALN-PCSSC on the following:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any condition that according to the investigator could interfere with the conduct of the study, such as but not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALN-PCSSC 200 milligram (mg) SC administration once at Day 1
Drug: ALN-PCSSC
ALN-PCSSC 300 mg SC administration once at Day 1
Drug: ALN-PCSSC
ALN-PCSSC 500 mg SC administration once at Day 1
Drug: ALN-PCSSC
Saline SC administration once at Day 1
Drug: Normal Saline
ALN-PCSSC 100 mg SC administration twice at Day 1 and Day 90
Drug: ALN-PCSSC
ALN-PCSSC 200 mg SC administration twice at Day 1 and Day 90
Drug: ALN-PCSSC
ALN-PCSSC 300 mg SC administration twice at Day 1 and Day 90
Drug: ALN-PCSSC
Saline SC administration twice at Day 1 and Day 90
Drug: Normal Saline
ALN-PCSSC is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis and is given as SC injections
Also known as: PCSK9 synthesis inhibitor, Inclisiran
Saline (sterile, normal, 0.9%) solution given as SC injections
Percentage Change in LDL-C From Baseline to Day 180
Percent Change in LDL-C (beta-quantification) from Baseline to Day 180 in MITT Population
Time frame: Baseline to 180 days
Percentage Change in LDL-C From Baseline to Day 90
Percent Change in LDL-C (beta-quantification) from Baseline to Day 90 in MITT Population
Time frame: Baseline to 90 days
Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210
This outcome measure evaluated the effects of both single- and double-dose inclisiran on LDL-C levels in the mITT population from baseline to Day 60, Day 120, and Day 210.
Time frame: Baseline, Day 60, Day 120, and Day 210
Number of Participants With an LDL-C Greater Than 80% of the Baseline Value at Day 180 and Day 210
This outcome measure evaluated the number of participants (single and double dose) in the mITT population with an LDL-C greater than 80% of the baseline value at Day 180 and Day 210.
Time frame: Baseline, Day 180, Day 210
Number of Participants With Individual Responsiveness as Measured By LDL-C Levels at Day 90 and Day 180
This outcome measure evaluated the individual responsiveness of participants to inclisiran (single and double dose) in the mITT population as defined by an LDL-C level of \<25 mg/deciliter \[dL\] at Day 90 and Day 180.
Time frame: Day 90, Day 180
Number of Participants With Greater Or Equal To 50% LDL-C Reduction From Baseline At Day 180
This outcome measure evaluated the number of participants (single and double dose) in the mITT population with an LDL-C reduction greater than 50% of the baseline value at Day 180.
Time frame: Baseline, Day 180
Percentage Change in PCSK9 Levels From Baseline at Day 180
This outcome measure evaluated the percent change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline to Day 180 in participants (single and double dose) in the mITT population.
Time frame: Baseline, Day 180
Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180
This outcome measure evaluated the percent change from baseline to Day 180 in cholesterol (total, high-density lipoprotein \[HDL\], non-HDL) and apolipoproteins (B, A1) in participants (single and double dose) in the mITT population.
Time frame: Baseline, Day 180
Number of Participants Who Attained Global Lipid Modification Targets for Level of Atherosclerotic Cardiovascular Disease Risk
This outcome measure evaluated the proportion of participants (single and double dose) in the mITT population who attained a global lipid modification target by baseline cardiovascular risk group, looking specifically at LDL-C levels (mg/dL) in the category of cardiovascular disease (CVD). CVD was defined as a participant who had at least 1 of the following: prior myocardial infarction, prior percutaneous coronary intervention, prior coronary artery bypass graft, prior stroke, prior transient ischemic attack, peripheral artery disease.
Time frame: Baseline, Day 180
Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180
This outcome measure evaluated the percent change from baseline to Day 180 in triglycerides, very-low-density lipoprotein (VLDL) cholesterol, lipoprotein(a), and high sensitivity C-reactive protein (hsCRP) in participants (single and double dose) in the mITT population.
Time frame: Baseline, Day 180
| Milestone | Inclisiran 200 mg (Single-dose) | Inclisiran 300 mg (Single-dose) | Inclisiran 500 mg (Single-dose) | Placebo (Single-dose) | Inclisiran 100 mg (Double-dose) | Inclisiran 200 mg (Double-dose) | Inclisiran 300 mg (Double-dose) | Placebo (Double-dose) |
|---|---|---|---|---|---|---|---|---|
| Started | 60 | 62 | 66 | 65 | 62 | 63 | 61 | 62 |
| Treated | 60 | 61 | 65 | 65 | 61 | 62 | 61 | 62 |
| Completed | 59 | 59 | 58 | 60 | 57 | 59 | 57 | 60 |
| Not completed | 1 | 3 | 8 | 5 | 5 | 4 | 4 | 2 |
Percent Change in LDL-C (beta-quantification) from Baseline to Day 180 in MITT Population
| Percent change | Placebo (Single Dose) | 200 mg (Single Dose) | 300 mg (Single Dose) | 500 mg (Single Dose) | Placebo (Double Dose) | 100 mg (Double Dose) | 200 mg (Double Dose) | 300 mg (Double Dose) |
|---|---|---|---|---|---|---|---|---|
| Percentage Change in LDL-C From Baseline to Day 180 | 2.1 (-2.9 to 7.2) | -27.9 (-33.1 to -22.7) | -38.4 (-43.6 to -33.2) | -41.9 (-47.2 to -36.7) | 1.8 (-2.6 to 6.3) | -35.5 (-40.0 to -31.0) | -44.9 (-49.3 to -40.4) | -52.6 (-57.1 to -48.1) |
Percent Change in LDL-C (beta-quantification) from Baseline to Day 90 in MITT Population
| Percent change | Single Dose 500 mg | Double Dose 100 mg | Single and Double Dose Placebo | Single and Double Dose 200 mg | Single and Double Dose 300 mg |
|---|---|---|---|---|---|
| Percentage Change in LDL-C From Baseline to Day 90 | -49 (-53.8 to -44.2) | -34.2 (-39.1 to -29.3) | -0.8 (-4.2 to 2.5) | -41.8 (-45.3 to -38.4) | -45.7 (-49.2 to -42.3) |
This outcome measure evaluated the effects of both single- and double-dose inclisiran on LDL-C levels in the mITT population from baseline to Day 60, Day 120, and Day 210.
| Percent change | Placebo (Single Dose) | Inclisiran 200 mg (Single Dose) | Inclisiran 300 mg (Single Dose) | Inclisiran 500 mg (Single Dose) | Placebo (Double Dose) | Inclisiran 100 mg (Double Dose) | Inclisiran 200 mg (Double Dose) | Inclisiran 300 mg (Double Dose) |
|---|---|---|---|---|---|---|---|---|
| Day 60 | -4.27 (-7.84 to -0.7) | -44.32 (-50.55 to -38.09) | -50.87 (-55.62 to -46.12) | -49.58 (-54.12 to -45.04) | -1.92 (-6.7 to 2.85) | -35.73 (-40.23 to -31.23) | -44.28 (-49.1 to -39.47) | -50.99 (-55.51 to -45.67) |
| Day 120 | -0.91 (-5.17 to 3.34) | -36.94 (-42.8 to -31.08) | -43.32 (-48.95 to -37.68) | -46.42 (-50.63 to -42.22) | 0.17 (-3.61 to 3.95) | -41.37 (-45.94 to -36.8) | -49.54 (-54.6 to -44.49) | -54.73 (-59.88 to -49.58) |
| Day 210 | 1.45 (-3.61 to 6.06) | -28.98 (-36.83 to -21.12) | -35.39 (-41.47 to -29.31) | -39.2 (-43.71 to -34.68) | 0.58 (-4.58 to 5.74) | -31.67 (-36.08 to -27.27) | -42.59 (-47.11 to -38.08) | -50.54 (-54.83 to -46.25) |
This outcome measure evaluated the number of participants (single and double dose) in the mITT population with an LDL-C greater than 80% of the baseline value at Day 180 and Day 210.
| Participants | Placebo (Single-dose) | Inclisiran 200 mg (Single-dose) | Inclisiran 300 mg (Single-dose) | Inclisiran 500 mg (Single-dose) | Placebo (Double-dose) | Inclisiran 100 mg (Double-dose) | Inclisiran 200 mg (Double-dose) | Inclisiran 300 mg (Double-dose) |
|---|---|---|---|---|---|---|---|---|
| Day 180 | 35 | 6 | 5 | 0 | 29 | 2 | 1 | 0 |
| Day 210 | 34 | 8 | 5 | 2 | 34 | 1 | 1 | 1 |
This outcome measure evaluated the individual responsiveness of participants to inclisiran (single and double dose) in the mITT population as defined by an LDL-C level of \<25 mg/deciliter \[dL\] at Day 90 and Day 180.
| Participants | Placebo (Single-dose) | Inclisiran 200 mg (Single-dose) | Inclisiran 300 mg (Single-dose) | Inclisiran 500 mg (Single-dose) | Placebo (Double-dose) | Inclisiran 100 mg (Double-dose) | Inclisiran 200 mg (Double-dose) | Inclisiran 300 mg (Double-dose) |
|---|---|---|---|---|---|---|---|---|
| Day 90 | 0 | 0 | 5 | 3 | 0 | 0 | 1 | 0 |
| Day 180 | 0 | 0 | 1 | 2 | 0 | 1 | 2 | 3 |
This outcome measure evaluated the number of participants (single and double dose) in the mITT population with an LDL-C reduction greater than 50% of the baseline value at Day 180.
| Participants | Placebo (Single-dose) | Inclisiran 200 mg (Single-dose) | Inclisiran 300 mg (Single-dose) | Inclisiran 500 mg (Single-dose) | Placebo (Double-dose) | Inclisiran 100 mg (Double-dose) | Inclisiran 200 mg (Double-dose) | Inclisiran 300 mg (Double-dose) |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Greater Or Equal To 50% LDL-C Reduction From Baseline At Day 180 | 0 | 9 | 19 | 16 | 0 | 14 | 27 | 32 |
This outcome measure evaluated the percent change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline to Day 180 in participants (single and double dose) in the mITT population.
| percent change | Placebo (Single Dose) | Inclisiran 200 mg (Single Dose) | Inclisiran 300 mg (Single Dose) | Inclisiran 500 mg (Single Dose) | Placebo (Double Dose) | Inclisiran 100 mg (Double Dose) | Inclisiran 200 mg (Double Dose) | Inclisiran 300 mg (Double Dose) |
|---|---|---|---|---|---|---|---|---|
| Percentage Change in PCSK9 Levels From Baseline at Day 180 | 2.2 ± 23.4 | -47.9 ± 21 | -56 ± 19.2 | -59.3 ± 18 | -1.2 ± 20.7 | -53.2 ± 20.9 | -66.2 ± 15.6 | -69.1 ± 12.1 |
This outcome measure evaluated the percent change from baseline to Day 180 in cholesterol (total, high-density lipoprotein \[HDL\], non-HDL) and apolipoproteins (B, A1) in participants (single and double dose) in the mITT population.
| percent change | Placebo (Single Dose) | Inclisiran 200 mg (Single Dose) | Inclisiran 300 mg (Single Dose) | Inclisiran 500 mg (Single Dose) | Placebo (Double Dose) | Inclisiran 100 mg (Double Dose) | Inclisiran 200 mg (Double Dose) | Inclisiran 300 mg (Double Dose) |
|---|---|---|---|---|---|---|---|---|
| Total Cholesterol | 1.8 ± 12.1 | -17.6 ± 19 | -23.7 ± 15.7 | -26.6 ± 10.7 | 0.7 ± 12.3 | -22.4 ± 12.4 | -26.8 ± 13 | 33.2 ± 11.3 |
| Non-HDL Cholesterol | 1.5 ± 16.7 | -25.1 ± 26.3 | -35.2 ± 20.2 | -36.9 ± 14 | 1.3 ± 16.9 | -31.7 ± 15.1 | -38.9 ± 16.8 | -46 ± 14.6 |
| HDL Cholesterol | 3.8 ± 15.6 | 4.4 ± 14.8 | 8.8 ± 11.1 | 6.9 ± 14 | 0.5 ± 12.5 | 7.6 ± 12.2 | 10.3 ± 15.3 | 8.6 ± 14.9 |
| Apolipoprotein B | 1.7 ± 14.7 | -22.9 ± 21 | -30.8 ± 18 | -33.1 ± 12.7 | 0.9 ± 13 | -27.8 ± 13.4 | -35 ± 15.8 | -40.9 ± 14.8 |
| Apolipoprotein A1 | 3.6 ± 10.6 | 2.9 ± 9.3 | 3.8 ± 8.9 | 4.1 ± 10.9 | 0.8 ± 8.3 | 5.5 ± 10.6 | 8.6 ± 11.5 | 6.2 ± 11.9 |
This outcome measure evaluated the proportion of participants (single and double dose) in the mITT population who attained a global lipid modification target by baseline cardiovascular risk group, looking specifically at LDL-C levels (mg/dL) in the category of cardiovascular disease (CVD). CVD was defined as a participant who had at least 1 of the following: prior myocardial infarction, prior percutaneous coronary intervention, prior coronary artery bypass graft, prior stroke, prior transient ischemic attack, peripheral artery disease.
| Participants | Placebo (Single-dose) | Inclisiran 200 mg (Single-dose) | Inclisiran 300 mg (Single-dose) | Inclisiran 500 mg (Single-dose) | Placebo (Double-dose) | Inclisiran 100 mg (Double-dose) | Inclisiran 200 mg (Double-dose) | Inclisiran 300 mg (Double-dose) |
|---|---|---|---|---|---|---|---|---|
| CVD | 45 | 43 | 46 | 33 | 45 | 41 | 39 | 42 |
| <70 mg/dL | 0 | 16 | 27 | 18 | 1 | 24 | 27 | 33 |
This outcome measure evaluated the percent change from baseline to Day 180 in triglycerides, very-low-density lipoprotein (VLDL) cholesterol, lipoprotein(a), and high sensitivity C-reactive protein (hsCRP) in participants (single and double dose) in the mITT population.
| percent change | Placebo (Single Dose) | Inclisiran 200 mg (Single Dose) | Inclisiran 300 mg (Single Dose) | Inclisiran 500 mg (Single Dose) | Placebo (Double Dose) | Inclisiran 100 mg (Double Dose) | Inclisiran 200 mg (Double Dose) | Inclisiran 300 mg (Double Dose) |
|---|---|---|---|---|---|---|---|---|
| Triglycerides | 6.4 (-15.9 to 21.9) | 1.1 (-18.5 to 17.8) | -12.8 (-27.8 to 7.8) | -12.2 (-25.6 to 7.7) | -3 (-17.2 to 22.6) | -6.3 (-17.6 to 10.9) | 0.7 (-22.4 to 11.3) | -14.2 (-26.4 to 5.4) |
| VLDL Cholesterol | 2.4 (-30.7 to 30.5) | -11.6 (-35.8 to 23.3) | -23.8 (-43 to -6.4) | -14.6 (-34.8 to 3.5) | 2.7 (-20 to 26.7) | -16.4 (-31.3 to 0) | -21.2 (-38.5 to 13.2) | -16 (-38.2 to 9.1) |
| Lipoprotein(a) | 0.5 (-13.9 to 14.8) | -14.3 (-29.5 to -3.5) | -14.3 (-25.4 to -5.6) | -18.2 (-35 to 1.6) | 0 (-10 to 12.4) | -14.9 (-26.2 to -1.9) | -17.3 (-31.9 to -7.7) | -25.6 (-38.5 to -15.2) |
| hsCRP | -5.3 (-40.8 to 28.4) | 7.1 (-30.7 to 70.9) | -16.2 (-45.8 to 50) | -19.8 (-50 to 32.7) | -20 (-50 to 30) | -12.5 (-42.9 to 29.4) | -16.3 (-34.6 to 24.3) | -16.7 (-50.9 to 33.3) |
Collected over Treatment Emergent Adverse Events up to Day 360. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Single Dose) | 0/65 (0%) | 3/65 (4.6%) | 50/65 (76.9%) |
| Inclisiran 200 mg (Single Dose) | 0/60 (0%) | 11/60 (18.3%) | 49/60 (81.7%) |
| Inclisiran 300 mg (Single Dose) | 0/61 (0%) | 11/61 (18%) | 49/61 (80.3%) |
| Inclisiran 500 mg (Single Dose) | 1/65 (1.5%) | 8/65 (12.3%) | 54/65 (83.1%) |
| Placebo (Double Dose) | 0/62 (0%) | 7/62 (11.3%) | 51/62 (82.3%) |
| Inclisiran 100 mg (Double Dose) | 0/61 (0%) | 13/61 (21.3%) | 47/61 (77%) |
| Inclisiran 200 mg (Double Dose) | 1/62 (1.6%) | 8/62 (12.9%) | 49/62 (79%) |
| Inclisiran 300 mg (Double Dose) | 0/61 (0%) | 9/61 (14.8%) | 51/61 (83.6%) |
| Event | Placebo (Single Dose) | Inclisiran 200 mg (Single Dose) | Inclisiran 300 mg (Single Dose) | Inclisiran 500 mg (Single Dose) | Placebo (Double Dose) | Inclisiran 100 mg (Double Dose) | Inclisiran 200 mg (Double Dose) | Inclisiran 300 mg (Double Dose) |
|---|---|---|---|---|---|---|---|---|
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/65 | 2/60 | 0/61 | 0/65 | 0/62 | 0/61 | 0/62 | 0/61 |
| Coronary artery diseaseCardiac disorders | 0/65 | 0/60 | 0/61 | 0/65 | 0/62 | 0/61 | 0/62 | 2/61 |
| Post procedural complicationInjury, poisoning and procedural complications | 0/65 | 0/60 | 0/61 | 1/65 | 0/62 | 0/61 | 2/62 | 0/61 |
| Myocardial infarctionCardiac disorders | 0/65 | 1/60 | 0/61 | 2/65 | 0/62 | 0/61 | 0/62 | 1/61 |
| Angina pectorisCardiac disorders | 0/65 | 1/60 | 1/61 | 1/65 | 0/62 | 0/61 | 0/62 | 0/61 |
| Inguinal herniaGastrointestinal disorders | 0/65 | 1/60 | 0/61 | 0/65 | 0/62 | 0/61 | 0/62 | 0/61 |
| VolvulusGastrointestinal disorders | 0/65 | 1/60 | 0/61 | 0/65 | 0/62 | 0/61 | 0/62 | 0/61 |
| Limb crushing injuryInjury, poisoning and procedural complications | 0/65 | 1/60 | 0/61 | 0/65 | 0/62 | 0/61 | 0/62 | 0/61 |
| OsteitisMusculoskeletal and connective tissue disorders | 0/65 | 1/60 | 0/61 | 0/65 | 0/62 | 0/61 | 0/62 | 0/61 |
| Oesophageal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/65 | 1/60 | 0/61 | 0/65 | 0/62 | 0/61 | 0/62 | 0/61 |
| Event | Placebo (Single Dose) | Inclisiran 200 mg (Single Dose) | Inclisiran 300 mg (Single Dose) | Inclisiran 500 mg (Single Dose) | Placebo (Double Dose) | Inclisiran 100 mg (Double Dose) | Inclisiran 200 mg (Double Dose) | Inclisiran 300 mg (Double Dose) |
|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 4/65 | 8/60 | 9/61 | 9/65 | 8/62 | 8/61 | 5/62 | 11/61 |
| MyalgiaMusculoskeletal and connective tissue disorders | 3/65 | 2/60 | 6/61 | 3/65 | 3/62 | 7/61 | 5/62 | 5/61 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/65 | 4/60 | 7/61 | 3/65 | 3/62 | 1/61 | 6/62 | 3/61 |
| DiarrhoeaGastrointestinal disorders | 1/65 | 1/60 | 4/61 | 4/65 | 2/62 | 3/61 | 7/62 | 5/61 |
| Back painMusculoskeletal and connective tissue disorders | 5/65 | 4/60 | 4/61 | 4/65 | 2/62 | 6/61 | 1/62 | 4/61 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 1/65 | 2/60 | 0/61 | 1/65 | 4/62 | 0/61 | 0/62 | 6/61 |
| FatigueGeneral disorders | 5/65 | 2/60 | 4/61 | 2/65 | 6/62 | 2/61 | 0/62 | 1/61 |
| DizzinessNervous system disorders | 3/65 | 1/60 | 2/61 | 2/65 | 6/62 | 3/61 | 3/62 | 3/61 |
| HeadacheNervous system disorders | 6/65 | 2/60 | 2/61 | 2/65 | 5/62 | 5/61 | 1/62 | 5/61 |
| InfluenzaInfections and infestations | 3/65 | 3/60 | 4/61 | 5/65 | 2/62 | 3/61 | 4/62 | 5/61 |
| Age, Categorical(Participants) | Placebo (Single-dose) | Inclisiran 200 mg (Single-dose) | Inclisiran 300 mg (Single-dose) | Inclisiran 500 mg (Single-dose) | Placebo (Double-dose) | Inclisiran 100 mg (Double-dose) | Inclisiran 200 mg (Double-dose) | Inclisiran 300 mg (Double-dose) | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 40 | 30 | 27 | 32 | 32 | 24 | 37 | 31 | 253 |
| >=65 years | 25 | 30 | 35 | 34 | 30 | 38 | 26 | 30 | 248 |
| Age, Continuous(years) | Placebo (Single-dose) | Inclisiran 200 mg (Single-dose) | Inclisiran 300 mg (Single-dose) | Inclisiran 500 mg (Single-dose) | Placebo (Double-dose) | Inclisiran 100 mg (Double-dose) | Inclisiran 200 mg (Double-dose) | Inclisiran 300 mg (Double-dose) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 62.0 ± 11.4 | 63.9 ± 10.8 | 64.1 ± 12.8 | 62.1 ± 12.4 | 62.8 ± 10.3 | 65.2 ± 9.4 | 62.3 ± 10.8 | 64.1 ± 9.4 | 63.6 ± 10.0 |
| Sex: Female, Male(Participants) | Placebo (Single-dose) | Inclisiran 200 mg (Single-dose) | Inclisiran 300 mg (Single-dose) | Inclisiran 500 mg (Single-dose) | Placebo (Double-dose) | Inclisiran 100 mg (Double-dose) | Inclisiran 200 mg (Double-dose) | Inclisiran 300 mg (Double-dose) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 23 | 21 | 20 | 19 | 29 | 23 | 24 | 16 | 175 |
| Male | 42 | 39 | 42 | 47 | 33 | 39 | 39 | 45 | 326 |
| Ethnicity (NIH/OMB)(Participants) | Placebo (Single-dose) | Inclisiran 200 mg (Single-dose) | Inclisiran 300 mg (Single-dose) | Inclisiran 500 mg (Single-dose) | Placebo (Double-dose) | Inclisiran 100 mg (Double-dose) | Inclisiran 200 mg (Double-dose) | Inclisiran 300 mg (Double-dose) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 4 | 3 | 1 | 2 | 2 | 6 | 4 | 29 |
| Not Hispanic or Latino | 58 | 56 | 59 | 65 | 60 | 60 | 57 | 57 | 472 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo (Single-dose) | Inclisiran 200 mg (Single-dose) | Inclisiran 300 mg (Single-dose) | Inclisiran 500 mg (Single-dose) | Placebo (Double-dose) | Inclisiran 100 mg (Double-dose) | Inclisiran 200 mg (Double-dose) | Inclisiran 300 mg (Double-dose) | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 | 1 | 0 | 2 | 0 | 1 | 6 |
| Asian | 0 | 2 | 2 | 2 | 1 | 1 | 0 | 1 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 4 | 4 | 2 | 0 | 3 | 2 | 2 | 1 | 18 |
| White | 59 | 53 | 56 | 63 | 58 | 57 | 61 | 58 | 465 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Region of Enrollment(Participants) | Placebo (Single-dose) | Inclisiran 200 mg (Single-dose) | Inclisiran 300 mg (Single-dose) | Inclisiran 500 mg (Single-dose) | Placebo (Double-dose) | Inclisiran 100 mg (Double-dose) | Inclisiran 200 mg (Double-dose) | Inclisiran 300 mg (Double-dose) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Canada | 8 | 8 | 7 | 12 | 10 | 10 | 7 | 9 | 71 |
| Netherlands | 22 | 21 | 21 | 21 | 20 | 20 | 23 | 21 | 169 |
| United States | 12 | 10 | 10 | 12 | 8 | 10 | 12 | 10 | 84 |
| United Kingdom | 11 | 11 | 11 | 11 | 10 | 9 | 11 | 12 | 86 |
| Germany | 12 | 10 | 13 | 10 | 14 | 13 | 10 | 9 | 91 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Jan 2016, a primary completion of Jun 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.
Results were first posted in May 2019, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inclisiran